As of 1:41pm ET
| -0.04 / -1.21%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +7.03% increase from the last price of 3.27.
The current consensus among 2 polled investment analysts is to Buy stock in PDL BioPharma Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.